HIV disease progression in Australia in the time of combination antiretroviral therapies

Medical Journal of Australia

Volumn 169, Issue 9, 1998, Pages 469-472

  Correll, Patricia K ^a   Law, Matthew G ^a   McDonald, Ann M ^a   Cooper, David A ^a   Kaldor, John M ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; AUSTRALIA; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORTALITY; RETROSPECTIVE STUDY; RISK; SURVIVAL; T LYMPHOCYTE;

EID: 0032476740     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.1998.tb123370.x     Document Type: Article

References (14)

1. Delta Coordinating Committee. Delta: a randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet 1996; 348: 283-291.
2. Hammer SM, Katzenstein DA, Hughes MD, et al. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4+ cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996; 335: 1081-1090.
3. CAESAR Coordinating Committee. Randomised trial of addition of lamivudine or lamivudine plus loviride-zidovudine-containing regimens for patients with HIV-1 infection: the CAESAR trial. Lancet 1997; 349: 1413-1421.
4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4+ cell counts of 200 per cubic millimeter or less. N Engl J Med 1997; 337: 725-733.
5. Centers for Disease Control. Conditions included in the 1993 AIDS surveillance case definition. MMWR Morb Mortal Wkly Rep 1992; 41: RR-17.
6. 6/L. AIDS 1995; 9: 145-151.
7. Tindall B, Swanson CE, Cooper DA. Development of AIDS in a cohort of HIV-seropositive homosexual men in Australia. Med J Aust 1990; 153: 260-265.
8. SAS statistical software version 6.12. Carey, NC: SAS Institute Incorporated, 1994.
9. HIV/AIDS Clinical Trials and Treatments Advisory Committee of the Australian National Council on AIDS and Related Diseases. Antiretroviral therapy for HIV infection: principles of use. Standard of care guidelines; October 1997. Sydney: HIV/AIDS Clinical Trials and Treatments Advisory Committee, 1997.
10. Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. BMJ 1997; 315: 1194-1199.
11. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. New Engl J Med 1998, 338: 853-860.
12. National Centre in HIV Epidemiology and Clinical Research. HIV/AIDS and related diseases in Australia: Annual Surveillance Report 1998. Sydney: National Centre in HIV Epidemiology and Clinical Research, 1998.
13. National Centre in HIV Epidemiology and Clinical Research. An epidemiological assessment of the HIV epidemic in Australia. Evaluation of the National HIV/AIDS Strategy 1993-1994 to 1995-1996. Canberra: Commonwealth Department of Health and Family Services, 1996.
14. Ioannidis JPA, Cappelleri JC, Schmid CH, Lau J. Impact of epidemic and individual heterogeneity on the population distribution of disease progression rates. Am J Epidemiol 1996; 144: 1074-1085.